



# 6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

[sciforum.net/conference/ECMC2020](http://sciforum.net/conference/ECMC2020)

sponsored by



pharmaceuticals

## Steroid derivatives: a promising class of bacterial efflux pump inhibitors?

**Fernando Durães<sup>1, 2</sup>, Ana Rita Neves<sup>1, 2</sup>, Joana Freitas-da-Silva<sup>2, 3</sup>, Annamária Kincses<sup>4</sup>, Eugénia Pinto<sup>2, 5</sup>, Paulo Costa<sup>2, 3</sup>, Madalena Pinto<sup>1, 2</sup>, Marta Correia-da-Silva<sup>1, 2</sup>, Gabriella Spengler<sup>4</sup>, Emília Sousa<sup>1, 2\*</sup>**

<sup>1</sup> Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, Portugal

<sup>2</sup> Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Portugal


<sup>3</sup> ICBAS – Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal

<sup>4</sup> Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Hungary

<sup>5</sup> Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Portugal

\* Corresponding author: [esousa@ff.up.pt](mailto:esousa@ff.up.pt)

# Steroid derivatives: a promising class of bacterial efflux pump inhibitors?



## Abstract:

The quest for compounds capable of **circumventing antimicrobial resistance** is important and urgent. Current research has been focusing not only in the search for new antibiotics, but also for “**helper**” **compounds**, capable of **blocking resistance mechanisms** and, therefore, regaining the activity of currently used antibacterial drugs. In this scope, **bacterial efflux pump inhibitors** arise as interesting compounds, as they can block this resistance mechanism and lead to increased efficacy of antibiotics.

Our group has been studying the **potential of steroid derivatives**. One amide derivative was found to display promising activity in antibacterial and **in synergy assays**, as well as in the **efflux pump inhibition assays**.


A screening for antimicrobial activity has been performed in Gram-positive and Gram-negative bacteria. Then, they were tested for their capability to modulate pump-mediated efflux. **The derivatives tested were able to increase the accumulation of ethidium bromide, which translates into efflux pump inhibition.**

**Keywords:** amides, antimicrobial, **bacterial efflux pumps**, **steroid derivatives**



# Introduction


A screening of an in-house library of structurally diverse compounds was performed



Four steroid derivatives emerged as promising


## Compounds 1-4

Can they also influence resistance mechanisms?



# Chemistry

The amide steroid derivatives were obtained through a coupling reaction with the desired amine



# Antibacterial activity

Compounds 1-4 were tested against ATCC susceptible strains (*Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 29213, *Pseudomonas aeruginosa* ATCC 27853 and *Enterococcus faecalis* ATCC 29212)

|          | <i>E. coli</i><br>ATCC 25922 |                  | <i>S. aureus</i><br>ATCC 29213 |     | <i>P. aeruginosa</i><br>ATCC 27853 |     | <i>E. faecalis</i><br>ATCC 29212 |     |
|----------|------------------------------|------------------|--------------------------------|-----|------------------------------------|-----|----------------------------------|-----|
|          | MIC <sup>1</sup>             | MBC <sup>2</sup> | MIC                            | MBC | MIC                                | MBC | MIC                              | MBC |
| <b>1</b> | 73-147                       | 147              | 37                             | 37  | 147                                | 147 | 37                               | 73  |
| <b>2</b> | >139                         | ND <sup>3</sup>  | >139                           | ND  | >139                               | ND  | >139                             | ND  |
| <b>3</b> | >139                         | ND               | >139                           | ND  | >139                               | ND  | >139                             | ND  |
| <b>4</b> | >139                         | ND               | >139                           | ND  | >139                               | ND  | 70                               | ND  |

<sup>1</sup> Minimum Inhibitory Concentration ( $\mu\text{M}$ )

<sup>2</sup> Minimum Bactericidal Concentration ( $\mu\text{M}$ )

<sup>3</sup> Not determined



# Antibacterial activity

**Compounds 1-4** were tested against resistant (*S. aureus* MRSA 272123) and a mutant strain with the *acrA* gene deleted (*Salmonella enterica* serovar Typhimurium SL1344), in order to access their capability of inhibiting bacterial efflux pumps

|          | <i>S. aureus</i><br>MRSA 272123 | <i>S. Typhimurium</i><br>SL1344 |
|----------|---------------------------------|---------------------------------|
|          | MIC <sup>1</sup>                | MIC                             |
| <b>1</b> | 12.5                            | 6.25                            |
| <b>2</b> | >100                            | >100                            |
| <b>3</b> | >100                            | >100                            |
| <b>4</b> | >100                            | >100                            |


<sup>1</sup> Minimum inhibitory concentration ( $\mu\text{M}$ )





# Bacterial Efflux Pump Inhibition

**Compounds 1-4** were assayed for their capability of inhibiting bacterial efflux pumps in *S. aureus* MRSA 272123 and *S. enterica* Typhimurium SL1344 through the accumulation of ethidium bromide, an efflux pump substrate, capable of increasing fluorescence





# Bacterial Efflux Pump Inhibition

All the derivatives showed a higher relative fluorescence index (RFI) than reserpine (positive control) after 60 minutes of incubation for *S. Typhimurium*, and three derivatives led to a higher RFI than reserpine in *S. aureus*

$$RFI = \frac{RF_{treated} - RF_{untreated}}{RF_{untreated}}$$

|           | <i>S. aureus</i><br>MRSA 272123 | <i>S. Typhimurium</i><br>SL1344 |
|-----------|---------------------------------|---------------------------------|
| Compound  | RFI                             |                                 |
| 1         | 0.14                            | 1.07                            |
| 2         | 2.33                            | 2.27                            |
| 3         | 1.77                            | 1.08                            |
| 4         | 0.80                            | 5.15                            |
| Reserpine | 0.70                            | 0.51                            |



# Antifungal activity

**Compound 1** was also tested for its antifungal activity in strains susceptible (*Candida albicans* ATCC 10231, *Aspergillus fumigatus* ATCC 46645 and *Tricophyton rubrum* FF5) and resistant to azoles (*Candida krusei* ATCC 6258, *C. albicans* D5 and *A. fumigatus* C111)

|          | <i>C. albicans</i><br>ATCC 10231 |                  | <i>C. albicans</i><br>D5 |     | <i>C. krusei</i><br>ATCC 6258 |     | <i>A. fumigatus</i><br>ATCC 46645 |      | <i>A. fumigatus</i><br>C111 |      | <i>T. rubrum</i><br>FF5 |     |
|----------|----------------------------------|------------------|--------------------------|-----|-------------------------------|-----|-----------------------------------|------|-----------------------------|------|-------------------------|-----|
|          | MIC                              | MFC <sup>1</sup> | MIC                      | MFC | MIC                           | MFC | MIC                               | MFC  | MIC                         | MFC  | MIC                     | MFC |
| <b>1</b> | 147                              | 147              | 147                      | 147 | 147                           | 147 | 294                               | >294 | 294                         | >294 | 147                     | 147 |

<sup>1</sup> Minimum Fungicidal Concentration ( $\mu\text{M}$ )

**Compound 1** was also able to inhibit the filamentation of *C. albicans*:

147  $\mu\text{M}$ : 100%; 74  $\mu\text{M}$ : 96.72%; 37  $\mu\text{M}$ : 41.22%; 18  $\mu\text{M}$ : 0%




# Conclusions

A steroid derivative emerged as a hit compound against bacteria and fungi

Three amide derivatives were synthesized

Future work: Synthesis of derivatives for SAR studies



The four derivatives inhibit bacterial efflux pumps

Studies on other antimicrobial and resistance mechanisms



6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

sponsored:




pharmaceuticals

## Conclusions

A steroid derivative emerged as a hit compound against bacteria and fungi

Three amide derivatives were synthesized

Future work:  
Synthesis of derivatives for SAR studies



The four derivatives inhibit bacterial efflux pumps

Studies on other antimicrobial and resistance mechanisms



6th International Electronic Conference on  
Medicinal Chemistry

1-30 November 2020

sponsored:




pharmaceuticals

## Conclusions

A steroid derivative emerged as a hit compound against bacteria and fungi

Three amide derivatives were synthesized

Future work:  
Synthesis of derivatives for SAR studies



**The four derivatives inhibit bacterial efflux pumps**

Studies on other antimicrobial and resistance mechanisms



6th International Electronic Conference on  
Medicinal Chemistry

1-30 November 2020

sponsored:




pharmaceuticals

## Conclusions

A steroid derivative emerged as a hit compound against bacteria and fungi

Three amide derivatives were synthesized



**Future work:  
Synthesis of  
derivatives  
for SAR studies**

The four derivatives inhibit bacterial efflux pumps

Studies on other antimicrobial and resistance mechanisms



**6th International Electronic Conference on Medicinal Chemistry**

1-30 November 2020

sponsored:




*pharmaceuticals*

# Conclusions

A steroid derivative emerged as a hit compound against bacteria and fungi

Three amide derivatives were synthesized

Future work:  
Synthesis of derivatives for SAR studies



The four derivatives inhibit bacterial efflux pumps

**Studies on other antimicrobial and resistance mechanisms**



6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

sponsored:



pharmaceuticals



# Acknowledgments



UNIÃO EUROPEIA  
Fundo Europeu  
de Desenvolvimento Regional



This research was supported by national funds through FCT—Foundation for Science and Technology within the scope of UIDB/04423/2020, UIDP/04423/2020 (Group of Natural Products and Medicinal Chemistry\_CIIMAR), and under the project PTDC/SAU-PUB/28736/2017 (reference POCI-01-0145-FEDER-028736), co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF and by FCT through national funds.

Fernando Durães and Ana Rita Neves acknowledge their PhD grants SFRH/BD/144681/2019 and SFRH/BD/114856/2016.

The authors thank Dr. Jessica Blair (Institute of Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK) for providing the *Salmonella* strain.



**6th International Electronic Conference on  
Medicinal Chemistry**

1-30 November 2020

sponsored:



pharmaceuticals



# 6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

[sciforum.net/conference/ECMC2020](http://sciforum.net/conference/ECMC2020)

sponsored by



pharmaceuticals

## Steroid derivatives: a promising class of bacterial efflux pump inhibitors?

**Fernando Durães<sup>1, 2</sup>, Ana Rita Neves<sup>1, 2</sup>, Joana Freitas-da-Silva<sup>2, 3</sup>, Annamária Kincses<sup>4</sup>, Eugénia Pinto<sup>2, 5</sup>, Paulo Costa<sup>2, 3</sup>, Madalena Pinto<sup>1, 2</sup>, Marta Correia-da-Silva<sup>1, 2</sup>, Gabriella Spengler<sup>4</sup>, Emília Sousa<sup>1, 2\*</sup>**

<sup>1</sup> Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, Portugal

<sup>2</sup> Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Portugal

<sup>3</sup> ICBAS – Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal

<sup>4</sup> Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Hungary

<sup>5</sup> Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Portugal

\* Corresponding author: [esousa@ff.up.pt](mailto:esousa@ff.up.pt)